NCT00877279已完成3 期
A Randomized,Blinded,Controlled,Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero® Soft, After Superficial to Mid Dermal Implantation for Correction of Mild Facial Wrinkles Over 4 Weeks.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 10
- 主要终点
- The severity of the facial wrinkle
研究概览
简要总结
This study is to determine the safety and effectiveness of Belotero® Soft compared to active comparator in the correction of mild facial wrinkles, such as nasolabial folds.
详细描述
The purpose of the study is to see if Belotero® Soft is safe and effective for correction of mild facial wrinkles, such as nasolabial folds. The second objective of the study is to see if Belotero® Soft works better than the active comparator. Subjects will receive Belotero® Soft injection to one side of the face and the active comparator to the other side of the face.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects must have bilateral facial wrinkles, such as nasolabial folds
排除标准
- •Other nasolabial fold correction within 6 months prior to study entry.
结局指标
主要结局
The severity of the facial wrinkle
时间窗: 2 weeks and 4 weeks
次要结局
- Investigator and subject assessments(2 weeks and 4 weeks)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
不适用
Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VIFacial WrinklesNCT00922623Merz North America, Inc.93
已完成
4 期
Belotero Post Approval StudyNasolabial FoldsNCT01635855Merz North America, Inc.117
已完成
4 期
Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3Physiological StressDisorder of AgingSkin DiseasesWrinklesNasolabial FoldsNCT01305187Merz Pharmaceuticals GmbH40
已完成
不适用
Evaluation of Effectiveness and Safety of Belotero Balance® (+) Lidocaine for Volume Augmentation of the Infraorbital HollowVolume Loss in the Infraorbital Hollow AreaNCT04594239Merz North America, Inc.150
已完成
2 期
Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium AdministrationAcquired Nephrogenic Diabetes InsipidusCongenital Nephrogenic Diabetes InsipidusNephrogenic Diabetes InsipidusAutosomal Dominant Polycystic Kidney DiseaseNCT05190744Mayo Clinic36